Continuing Education Activity

Hyperemesis gravidarum refers to intractable vomiting during pregnancy, leading to weight loss and volume depletion, resulting in ketonuria and/or ketonemia. There is no consensus on specific diagnostic criteria, but it generally refers to the severe end of the spectrum regarding nausea and vomiting in pregnancy. This activity highlights the role of the interprofessional team in the prevention and management of hyperemesis gravidarum.

Objectives:

• Describe the pathophysiology of hyperemesis gravidarum.
• Review the presentation of pregnant women presenting with hyperemesis gravidarum (HG).
• Outline the treatment and management options available for women with hyperemesis gravidarum.
• Explain interprofessional team strategies for improving care coordination and outcomes in pregnant women presenting with hyperemesis gravidarum.

Introduction

Hyperemesis gravidarum refers to intractable vomiting during pregnancy, leading to weight loss and volume depletion, resulting in ketonuria and/or ketonemia.[1][2] There is no consensus on specific diagnostic criteria, but it generally refers to the severe end of the spectrum regarding nausea and vomiting in pregnancy. It occurs in approximately two percent of all pregnancies in the United States.[3] It can significantly impact the quality of life of women and their families and, unfortunately, may be very challenging to treat.[4]

Etiology

The etiology of hyperemesis gravidarum is largely unknown, but several theories exist (see pathophysiology). There are, however, risk factors associated with the development of hyperemesis during pregnancy. Increased placental mass in the setting of a molar or multiple gestations has been associated with a higher risk of hyperemesis gravidarum. Additionally, women who experience nausea and vomiting outside of pregnancy due to the consumption of estrogen-containing medications, exposure to motion, or have a history of migraines are at higher risk of experiencing nausea and vomiting during pregnancy. Some studies also suggest a higher risk of hyperemesis in women with first-degree relatives, for instance, if her mother or sister experienced hyperemesis gravidarum.[5]

Protective factors include the use of multivitamins before six weeks of gestational age and maternal cigarette smoking.[6]

Epidemiology

Up to ninety percent of women experience nausea during pregnancy. Studies showed that approximately 27 to 30 percent of women experience only nausea, while vomiting may be seen in 28 to 52 percent of all pregnancies.[7][8] The incidence of hyperemesis gravidarum ranges from 0.3 to 3 percent, depending on the literature source. Geographically, hyperemesis appears to be more common in western counties.[9]

Pathophysiology

The exact cause of hyperemesis gravidarum remains unclear. However, there are several theories for what may contribute to the development of this disease process.

Hormone Changes

• Levels of human chorionic gonadotropin (hCG) have been implicated. hCG levels peak during the first trimester, corresponding to the typical onset of hyperemesis symptoms. Some studies show a correlation between higher hCG concentrations and hyperemesis.[10][11] However, this data has not been consistent.[12]
• Estrogen is also thought to contribute to nausea and vomiting in pregnancy. Estradiol levels increase early in pregnancy and decrease later, mirroring the typical course of nausea and vomiting in pregnancy. Additionally, nausea and vomiting are the known side effects of estrogen-containing medications. As the level of estrogen increases, so does the incidence of vomiting.[13]

Changes in the Gastrointestinal System

• It is well-known that the lower esophageal sphincter relaxes during pregnancy due to the elevations in estrogen and progesterone. This leads to an increased incidence of gastroesophageal reflux disease (GERD) symptoms in pregnancy, and one symptom of GERD is nausea.[14] Studies examining the relationship between GERD and emesis in pregnancy report conflicting results.

Genetics

• An increased risk of hyperemesis gravidarum has been demonstrated among women with family members who also experienced hyperemesis gravidarum.
• Two genes, GDF15 and IGFBP7, have been potentially linked to the development of hyperemesis gravidarum.[15]

History and Physical

Careful history taking in women with suspected or confirmed hyperemesis gravidarum should include their pregnancy status, estimated gestational age, history of complications during prior pregnancies, the frequency and severity of nausea and vomiting, any interventions done to treat her symptom(s), and the outcomes of the attempted interventions. The average onset of symptoms happens approximately 5 to 6 weeks into gestation.[8]

The physical exam should include fetal heart rate (depending on gestational age) and an examination of fluid status, including an examination of blood pressure, heart rate, mucous membrane dryness, capillary refill, and skin turgor. A patient weight should be obtained for comparison to previous and future weights. If indicated, abdominal examination and pelvic examination should occur to determine the presence or absence of tenderness to palpation.

Evaluation

There is no single accepted definition for hyperemesis gravidarum. However, it generally refers to extreme cases of nausea and vomiting during pregnancy. It is a clinical diagnosis. The criteria for diagnosis include vomiting that causes significant dehydration (as evidenced by ketonuria or electrolyte abnormalities) and weight loss (the most commonly cited marker for this is the loss of at least five percent of the patient’s pre-pregnancy weight) in the setting of pregnancy without any other underlying pathological cause for vomiting. Significant abdominal tenderness, pelvic tenderness, or vaginal bleeding should prompt a workup for alternative diagnoses.

The evaluation should include urinalysis to check for ketonuria and specific gravity, in addition to a complete blood count and electrolyte evaluation. An elevation in hemoglobin or hematocrit may be due to hemoconcentration in the setting of dehydration. Significant dehydration may result in acute kidney injury as evidenced by elevated serum creatinine, blood urea nitrogen, and reduced glomerular filtration. Potassium, calcium, magnesium, sodium, and bicarbonate may be affected by prolonged bouts of vomiting and reduced oral intake of fluids. Thyroid tests, lipase, and liver function testing may also be completed to evaluate for alternate diagnoses.

Radiographic studies may be appropriate to rule out alternate diagnoses. Obstetrical ultrasounds may be considered to rule out multiple gestations, ectopic pregnancy, and gestational trophoblastic disease, depending on the patient’s history and prior obstetrical evaluations. Magnetic resonance imaging (MRI) may be used to assess alternative diagnoses, such as appendicitis.

Treatment / Management

Treatment should be guided by the American College of Obstetrics and Gynecology (ACOG) Nausea and Vomiting in Pregnancy guidelines. Initial treatment should begin with non-pharmacologic interventions such as switching the patient’s prenatal vitamins to folic acid supplementation only, using ginger supplementation (250 mg orally 4 times daily) as needed and applying acupressure wristbands.[16][17] If the patient continues to experience significant symptoms, the first-line pharmacologic therapy should include a combination of vitamin B6 (pyridoxine) and doxylamine. Three dosing regiments are endorsed by ACOG, including pyridoxine 10 to 25 mg orally with 12.5 mg of doxylamine three or four times per day, 10 mg of pyridoxine and 10 mg of doxylamine up to 4 times per day, or 20 mg of pyridoxine and 20 mg of doxylamine up to 2 times per day. These are all FDA pregnancy category A medications.

Second-line medications include antihistamines and dopamine antagonists such as dimenhydrinate 25 to 50 mg every 4 to 6 hours orally, diphenhydramine 25 to 50 mg every 4 to 6 hours orally, prochlorperazine 25 mg every 12 hours rectally, or promethazine 12.5 to 25 mg every 4 to 6 hours orally or rectally. If the patient continues to experience significant symptoms without exhibiting signs of dehydration, metoclopramide, ondansetron, or promethazine may be given orally. In the case of dehydration, intravenous fluid boluses or continuous infusions of normal saline should be given in addition to intravenous metoclopramide, ondansetron, or promethazine. Electrolytes should be replaced as needed. Severe refractory cases of hyperemesis gravidarum may respond to intravenous or intramuscular chlorpromazine 25 to 50 mg or methylprednisolone 16 mg every 8 hours, orally or intravenously.[18]

Differential Diagnosis

The diagnosis of hyperemesis gravidarum is clinical and largely a diagnosis of exclusion. The list of potential differential diagnoses for patients with similar symptoms is quite extensive. It can include:[19]

Gastrointestinal Conditions

• Gastroenteritis
• Gastroparesis
• Achalasia
• Biliary tract disease
• Hepatitis
• Intestinal obstruction
• Peptic ulcer disease
• Pancreatitis
• Appendicitis

Genitourinary Conditions

• Pyelonephritis
• Uremia
• Ovarian torsion
• Kidney stones
• Degenerating uterine leiomyoma

Metabolic Conditions

• Diabetic ketoacidosis
• Porphyria
• Addison disease
• Hyperthyroidism
• Hyperparathyroidism

Neurologic Disorders

• Pseudotumor cerebri
• Vestibular lesions
• Migraine headaches
• Tumors of the central nervous system
• Lymphocytic hypophysitis

Miscellaneous Conditions

• Drug toxicity or intolerance

Psychologic Conditions

Pregnancy-related conditions

• Acute fatty liver of pregnancy Preeclampsia

It is important to evaluate women presenting with (HG) for gestational trophoblastic disease (GTD) and multiple gestations as they may also present with severe nausea and vomiting in the first trimester of pregnancy. The workup may begin with an obstetric ultrasound scan, which will confirm the diagnosis in most cases. Other first-trimester obstetric concerns include ectopic pregnancy, which is more likely to include abdominal pain, syncope, or vaginal bleeding and can again be evaluated by obstetrical ultrasound and beta-hCG levels.

The onset of nausea and vomiting after nine weeks should spark concern for alternative diagnoses. Preeclampsia, HELLP (hemolysis, elevated liver enzymes, and low platelets), and acute fatty liver of pregnancy typically present themselves during the late second or third trimester of pregnancy.

Non-obstetrical causes for nausea and vomiting can also occur during pregnancy and should always remain on the differential, keeping in mind that pregnant patients are considered to be at higher risk of blood clotting; therefore, diagnoses that result in ischemia or thrombus formation may be more common during pregnancy. Gastrointestinal causes such as gastroenteritis, small bowel obstruction, gastroparesis, peptic ulcer disease, cholecystitis, pancreatitis, hepatitis, and appendicitis should be considered. Pyelonephritis, urinary tract infections, renal stones, and ovarian torsion may also include vomiting. Metabolic derangements such as diabetic ketoacidosis, hyperthyroidism, and hyperparathyroidism may also have similar symptoms. Neurologic disorders such as migraine, intracranial hemorrhage, pseudotumor cerebri, and venous sinus thrombosis can also cause vomiting but are likely to have associated headaches or neurologic deficits. Psychiatric disorders such as anxiety and depression may also result in vomiting, toxic ingestions, and myocardial ischemia.

Pertinent Studies and Ongoing Trials

Validating the Effect of Ondansetron and Mirtazapine in Treating Hyperemesis Gravidarum: A Double-Blind Randomised Placebo-Controlled Multicentre Trial. (ongoing trial till 2023) Chewing Gum Containing Vitamin-c to Treat Emesis Gravidarum: a Randomized Controlled Trial. (ongoing trial till March 2022)

Staging

Modified Pregnancy-Unique Quantification of Emesis and Nausea (PUQE Score) 

No single measure can easily define, quantify or evaluate the treatment of hyperemesis. Still, an English pregnancy-specific questionnaire, PUQE (Pregnancy-Unique Quantification of Emesis), has been developed to assess the severity of emesis (nausea and vomiting) in pregnancy. This questionnaire contains three questions regarding the time-span of nausea, vomiting, and retching, respectively, as well as one question assessing the global psychological and physical quality of life (QOL). Initially, the questionnaire evaluated symptoms during the last 12 hours, but it has been modified to encompass 24 hours and the whole of the first trimester of pregnancy.[20] PUQE-score has been validated to correlate with the inability to take iron supplementation in pregnancy, risk of hospitalization due to HG or severe nausea and vomiting in pregnancy (NVP), and increased health care costs due to NVP, and reduced well-being/QOL (quality of life).

Prognosis

Nausea and vomiting in pregnancy are common. Symptoms usually begin prior to 9 weeks gestation, and the majority of cases are resolved by week 20 of gestation. A minority of patients, approximately 3 percent, will continue to experience vomiting during the third trimester. Approximately 10 percent of patients with hyperemesis gravidarum will be affected throughout the pregnancy.[21] It is reassuring to know that hyperemesis does not appear to become more likely with each pregnancy and that after one pregnancy with (HG), the following pregnancy may be different.[22]

Complications

As hyperemesis gravidarum involves at least two patients, both the mother and the fetus(s) must be considered when discussing complications.

Maternal Complications

In severe cases of hyperemesis, complications include vitamin deficiency, dehydration, and malnutrition, if not treated appropriately. Wernicke encephalopathy, caused by vitamin-B1 deficiency, can lead to death and permanent disability if left untreated.[23][24][25] Additionally, there have been case reports of injuries secondary to forceful and frequent vomiting, including esophageal rupture and pneumothorax.[26][27][28] Electrolyte abnormalities such as hypokalemia can also cause significant morbidity and mortality.[29] Additionally, patients with hyperemesis may have higher rates of depression and anxiety during pregnancy.[30]

Fetal Complications

Studies report conflicting information regarding the incidence of low birth weight and premature infants in the setting of nausea and vomiting in pregnancy.[31][32][33][34] However, studies have not shown an association between hyperemesis and perinatal or neonatal mortality.[34] The frequency of congenital anomalies does not appear to increase in patients with hyperemesis.[31]

Consultations

Primary healthcare providers should refer women presenting with (HG) to obstetric providers as it is the most severe form of nausea and vomiting in pregnancy. Inpatient management is indicated for intravenous antiemetics and fluids in the setting of refractory symptoms, failed outpatient treatment, severe dehydration, or electrolyte disturbance. Management of women with (HG) should involve a multidisciplinary team to improve outcomes for both the mother and the baby.

Deterrence and Patient Education

Daily intake of a multivitamin with folic acid at least one month prior to conception not only reduces the risk of congenital anomalies such as neural tube defects but has also been associated with reduced frequency and severity of nausea and vomiting in pregnancy.[19]

Enhancing Healthcare Team Outcomes

Women presenting with HG should be managed by an interprofessional team that provides comprehensive care and an integrated approach to help achieve the best patient-centered outcomes. Midwives and primary health care providers should ensure timely referral of women with HG to avoid unnecessary delay in the most appropriate management of these women. Clear and legible communication among the interprofessional team members will help deliver the best standard of care for women with HG. Women with severe and intractable (HG) should be managed in the hospital, and the nurse should document all her observations accurately. The nurse should inform the obstetric provider of any untoward change in the maternal observations. Assessment of fetal wellbeing plays a very crucial role in the management of women with (HG). If there is any deterioration of the general condition of the woman with (HG), early transfer to critical care units should be considered. Intensivists and critical care team members should be involved in managing women presenting with severe and/or intractable (HG). The woman's preferences, views, and choices should be respected at all times. [Level 5]

Review Questions

• Access free multiple choice questions on this topic.
• Click here for a simplified version.
• Comment on this article.

References

1.

Erick M, Cox JT, Mogensen KM. ACOG Practice Bulletin 189: Nausea and Vomiting of Pregnancy. Obstet Gynecol. 2018 May;131(5):935. [PubMed: 29683896]

2.

Goodwin TM. Hyperemesis gravidarum. Clin Obstet Gynecol. 1998 Sep;41(3):597-605. [PubMed: 9742356]

3.

Matthews A, Haas DM, O'Mathúna DP, Dowswell T. Interventions for nausea and vomiting in early pregnancy. Cochrane Database Syst Rev. 2015 Sep 08;2015(9):CD007575. [PMC free article: PMC7196889] [PubMed: 26348534]

4.

Lacasse A, Rey E, Ferreira E, Morin C, Bérard A. Nausea and vomiting of pregnancy: what about quality of life? BJOG. 2008 Nov;115(12):1484-93. [PubMed: 18752585]

5.

Fejzo MS, Ingles SA, Wilson M, Wang W, MacGibbon K, Romero R, Goodwin TM. High prevalence of severe nausea and vomiting of pregnancy and hyperemesis gravidarum among relatives of affected individuals. Eur J Obstet Gynecol Reprod Biol. 2008 Nov;141(1):13-7. [PMC free article: PMC2660884] [PubMed: 18752885]

6.

Czeizel AE, Dudas I, Fritz G, Técsöi A, Hanck A, Kunovits G. The effect of periconceptional multivitamin-mineral supplementation on vertigo, nausea and vomiting in the first trimester of pregnancy. Arch Gynecol Obstet. 1992;251(4):181-5. [PubMed: 1503509]

7.

Hinkle SN, Mumford SL, Grantz KL, Silver RM, Mitchell EM, Sjaarda LA, Radin RG, Perkins NJ, Galai N, Schisterman EF. Association of Nausea and Vomiting During Pregnancy With Pregnancy Loss: A Secondary Analysis of a Randomized Clinical Trial. JAMA Intern Med. 2016 Nov 01;176(11):1621-1627. [PMC free article: PMC6191846] [PubMed: 27669539]

8.

Gadsby R, Barnie-Adshead AM, Jagger C. A prospective study of nausea and vomiting during pregnancy. Br J Gen Pract. 1993 Jun;43(371):245-8. [PMC free article: PMC1372422] [PubMed: 8373648]

9.

Lacasse A, Rey E, Ferreira E, Morin C, Bérard A. Epidemiology of nausea and vomiting of pregnancy: prevalence, severity, determinants, and the importance of race/ethnicity. BMC Pregnancy Childbirth. 2009 Jul 02;9:26. [PMC free article: PMC2713199] [PubMed: 19573237]

10.

Kimura M, Amino N, Tamaki H, Ito E, Mitsuda N, Miyai K, Tanizawa O. Gestational thyrotoxicosis and hyperemesis gravidarum: possible role of hCG with higher stimulating activity. Clin Endocrinol (Oxf). 1993 Apr;38(4):345-50. [PubMed: 8319364]

11.

Goodwin TM, Montoro M, Mestman JH, Pekary AE, Hershman JM. The role of chorionic gonadotropin in transient hyperthyroidism of hyperemesis gravidarum. J Clin Endocrinol Metab. 1992 Nov;75(5):1333-7. [PubMed: 1430095]

12.

Soules MR, Hughes CL, Garcia JA, Livengood CH, Prystowsky MR, Alexander E. Nausea and vomiting of pregnancy: role of human chorionic gonadotropin and 17-hydroxyprogesterone. Obstet Gynecol. 1980 Jun;55(6):696-700. [PubMed: 7383455]

13.

Goldzieher JW, Moses LE, Averkin E, Scheel C, Taber BZ. A placebo-controlled double-blind crossover investigation of the side effects attributed to oral contraceptives. Fertil Steril. 1971 Sep;22(9):609-23. [PubMed: 4105854]

14.

Brzana RJ, Koch KL. Gastroesophageal reflux disease presenting with intractable nausea. Ann Intern Med. 1997 May 01;126(9):704-7. [PubMed: 9139556]

15.

Fejzo MS, Sazonova OV, Sathirapongsasuti JF, Hallgrímsdóttir IB, Vacic V, MacGibbon KW, Schoenberg FP, Mancuso N, Slamon DJ, Mullin PM., 23andMe Research Team. Placenta and appetite genes GDF15 and IGFBP7 are associated with hyperemesis gravidarum. Nat Commun. 2018 Mar 21;9(1):1178. [PMC free article: PMC5862842] [PubMed: 29563502]

16.

Viljoen E, Visser J, Koen N, Musekiwa A. A systematic review and meta-analysis of the effect and safety of ginger in the treatment of pregnancy-associated nausea and vomiting. Nutr J. 2014 Mar 19;13:20. [PMC free article: PMC3995184] [PubMed: 24642205]

17.

Werntoft E, Dykes AK. Effect of acupressure on nausea and vomiting during pregnancy. A randomized, placebo-controlled, pilot study. J Reprod Med. 2001 Sep;46(9):835-9. [PubMed: 11584487]

18.

McParlin C, O'Donnell A, Robson SC, Beyer F, Moloney E, Bryant A, Bradley J, Muirhead CR, Nelson-Piercy C, Newbury-Birch D, Norman J, Shaw C, Simpson E, Swallow B, Yates L, Vale L. Treatments for Hyperemesis Gravidarum and Nausea and Vomiting in Pregnancy: A Systematic Review. JAMA. 2016 Oct 04;316(13):1392-1401. [PubMed: 27701665]

19.

Committee on Practice Bulletins-Obstetrics. ACOG Practice Bulletin No. 189: Nausea And Vomiting Of Pregnancy. Obstet Gynecol. 2018 Jan;131(1):e15-e30. [PubMed: 29266076]

20.

Lacasse A, Rey E, Ferreira E, Morin C, Bérard A. Validity of a modified Pregnancy-Unique Quantification of Emesis and Nausea (PUQE) scoring index to assess severity of nausea and vomiting of pregnancy. Am J Obstet Gynecol. 2008 Jan;198(1):71.e1-7. [PubMed: 18166311]

21.

Goodwin TM. Hyperemesis gravidarum. Obstet Gynecol Clin North Am. 2008 Sep;35(3):401-17, viii. [PubMed: 18760227]

22.

Nurmi M, Rautava P, Gissler M, Vahlberg T, Polo-Kantola P. Recurrence patterns of hyperemesis gravidarum. Am J Obstet Gynecol. 2018 Nov;219(5):469.e1-469.e10. [PubMed: 30121224]

23.

Togay-Işikay C, Yiğit A, Mutluer N. Wernicke's encephalopathy due to hyperemesis gravidarum: an under-recognised condition. Aust N Z J Obstet Gynaecol. 2001 Nov;41(4):453-6. [PubMed: 11787926]

24.

Spruill SC, Kuller JA. Hyperemesis gravidarum complicated by Wernicke's encephalopathy. Obstet Gynecol. 2002 May;99(5 Pt 2):875-7. [PubMed: 11975941]

25.

Kim YH, Lee SJ, Rah SH, Lee JH. Wernicke's encephalopathy in hyperemesis gravidarum. Can J Ophthalmol. 2002 Feb;37(1):37-8. [PubMed: 11865957]

26.

Eroğlu A, Kürkçüoğlu C, Karaoğlanoğlu N, Tekinbaş C, Cesur M. Spontaneous esophageal rupture following severe vomiting in pregnancy. Dis Esophagus. 2002;15(3):242-3. [PubMed: 12444998]

27.

Liang SG, Ooka F, Santo A, Kaibara M. Pneumomediastinum following esophageal rupture associated with hyperemesis gravidarum. J Obstet Gynaecol Res. 2002 Jun;28(3):172-5. [PubMed: 12214835]

28.

Garg R, Sanjay, Das V, Usman K, Rungta S, Prasad R. Spontaneous pneumothorax: an unusual complication of pregnancy--a case report and review of literature. Ann Thorac Med. 2008 Jul;3(3):104-5. [PMC free article: PMC2700443] [PubMed: 19561889]

29.

Walch A, Duke M, Auty T, Wong A. Profound Hypokalaemia Resulting in Maternal Cardiac Arrest: A Catastrophic Complication of Hyperemesis Gravidarum? Case Rep Obstet Gynecol. 2018;2018:4687587. [PMC free article: PMC6087565] [PubMed: 30151287]

30.

Mitchell-Jones N, Gallos I, Farren J, Tobias A, Bottomley C, Bourne T. Psychological morbidity associated with hyperemesis gravidarum: a systematic review and meta-analysis. BJOG. 2017 Jan;124(1):20-30. [PubMed: 27418035]

31.

Veenendaal MV, van Abeelen AF, Painter RC, van der Post JA, Roseboom TJ. Consequences of hyperemesis gravidarum for offspring: a systematic review and meta-analysis. BJOG. 2011 Oct;118(11):1302-13. [PubMed: 21749625]

32.

Weigel MM, Weigel RM. Nausea and vomiting of early pregnancy and pregnancy outcome. An epidemiological study. Br J Obstet Gynaecol. 1989 Nov;96(11):1304-11. [PubMed: 2611169]

33.

Chin RK, Lao TT. Low birth weight and hyperemesis gravidarum. Eur J Obstet Gynecol Reprod Biol. 1988 Jul;28(3):179-83. [PubMed: 3208964]

34.

Vandraas KF, Vikanes AV, Vangen S, Magnus P, Støer NC, Grjibovski AM. Hyperemesis gravidarum and birth outcomes-a population-based cohort study of 2.2 million births in the Norwegian Birth Registry. BJOG. 2013 Dec;120(13):1654-60. [PubMed: 24021026]

Disclosure: Lindsey Jennings declares no relevant financial relationships with ineligible companies.

Disclosure: Heba Mahdy declares no relevant financial relationships with ineligible companies.